181 related articles for article (PubMed ID: 21392560)
1. Progress in understanding adjuvant immunotoxicity mechanisms.
Batista-Duharte A; Lindblad EB; Oviedo-Orta E
Toxicol Lett; 2011 Jun; 203(2):97-105. PubMed ID: 21392560
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of immunological adjuvants. Where is the cut-off?
Batista-Duharte A; Martínez DT; Carlos IZ
Biomed Pharmacother; 2018 Sep; 105():616-624. PubMed ID: 29894962
[TBL] [Abstract][Full Text] [Related]
3. Comparison of immune and adverse effects induced by AdjuVac and Freund's complete adjuvant in New Zealand white rabbits (Oryctolagus cuniculus).
Powers JG; Nash PB; Rhyan JC; Yoder CA; Miller LA
Lab Anim (NY); 2007 Oct; 36(9):51-8. PubMed ID: 17885664
[TBL] [Abstract][Full Text] [Related]
4. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant activity of cytokines.
Tovey MG; Lallemand C
Methods Mol Biol; 2010; 626():287-309. PubMed ID: 20099135
[TBL] [Abstract][Full Text] [Related]
6. Importance of immunotoxicity in safety assessment: a medical toxicologist's perspective.
Descotes J
Toxicol Lett; 2004 Apr; 149(1-3):103-8. PubMed ID: 15093254
[TBL] [Abstract][Full Text] [Related]
7. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of aluminum adjuvant toxicity and autoimmunity in pediatric populations.
Tomljenovic L; Shaw CA
Lupus; 2012 Feb; 21(2):223-30. PubMed ID: 22235057
[TBL] [Abstract][Full Text] [Related]
9. Freund's complete and incomplete adjuvants, preparation, and quality control standards for experimental laboratory animals use.
Stewart-Tull DE
Methods Mol Biol; 2010; 626():59-72. PubMed ID: 20099121
[TBL] [Abstract][Full Text] [Related]
10. Unmet needs in modern vaccinology: adjuvants to improve the immune response.
Leroux-Roels G
Vaccine; 2010 Aug; 28 Suppl 3():C25-36. PubMed ID: 20713254
[TBL] [Abstract][Full Text] [Related]
11. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Montanide adjuvants, IMS 3012 (Nanoparticle), ISA 206 and ISA 35 (Emulsion based) along with incomplete Freund's adjuvant for hyperimmunization of equines used for production of polyvalent snake antivenom.
Waghmare A; Deopurkar RL; Salvi N; Khadilkar M; Kalolikar M; Gade SK
Vaccine; 2009 Feb; 27(7):1067-72. PubMed ID: 19100805
[TBL] [Abstract][Full Text] [Related]
13. Antitumor vaccination: where we stand.
Bocchia M; Bronte V; Colombo MP; De Vincentiis A; Di Nicola M; Forni G; Lanata L; Lemoli RM; Massaia M; Rondelli D; Zanon P; Tura S
Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658
[TBL] [Abstract][Full Text] [Related]
14. [Improvement of veterinary vaccines through the use of new adjuvants].
Hilgers LA
Tijdschr Diergeneeskd; 1991 May; 116(10):508-12. PubMed ID: 2048061
[TBL] [Abstract][Full Text] [Related]
15. The science of adjuvants.
Kwissa M; Kasturi SP; Pulendran B
Expert Rev Vaccines; 2007 Oct; 6(5):673-84. PubMed ID: 17931149
[TBL] [Abstract][Full Text] [Related]
16. Present and future of in vitro immunotoxicology in drug development.
Galbiati V; Mitjans M; Corsini E
J Immunotoxicol; 2010; 7(4):255-67. PubMed ID: 20735150
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant effects of saponins on animal immune responses.
Rajput ZI; Hu SH; Xiao CW; Arijo AG
J Zhejiang Univ Sci B; 2007 Mar; 8(3):153-61. PubMed ID: 17323426
[TBL] [Abstract][Full Text] [Related]
18. [Opioids and their immunomodulatory properties].
Blahoutová V; Zajícová A; Wilczek H; Holán V
Cas Lek Cesk; 2003; 142(4):244-7. PubMed ID: 12841129
[TBL] [Abstract][Full Text] [Related]
19. Starch microparticles as vaccine adjuvant.
Rydell N; Stertman L; Sjöholm I
Expert Opin Drug Deliv; 2005 Sep; 2(5):807-28. PubMed ID: 16296780
[TBL] [Abstract][Full Text] [Related]
20. [Immunotoxicity assessment in the preclinical study of biologically active compounds].
Uteshev BS; Arzamastsev EV
Eksp Klin Farmakol; 1996; 59(3):3-8. PubMed ID: 8974580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
